Frequently Asked Questions about the American Course on Drug Development and Regulatory Sciences (ACDRS)

ACDRS Course

  Course Description
when For ACDRS 2022 Course: January 2022 to November 2022
where For ACDRS 2022 Course: online and, if possible, transition to University of California, Washington Center in Washington, DC
day and time There are six sessions. Each online session is five half-days long (10am-3pm ET).
In-person attendance, if possible, is 3 full-days long (8-5pm ET)
location For 2022: online and, if possible, transition to Washington, DC
who should attend

The course is for:

  • the biopharmaceutical industry (including medical device manufacturers) and their service industries
  • industry, government, and academic scientists
  • decision- and policy-makers who have a good grounding in medical product development basics and can benefit from a more in-depth, comprehensive and systematic immersion into modern medical product development, regulation, and market introduction.

The Course specifically targets the following professionals:

  • Drug discovery and non-clinical development team leaders
  • Drug discovery and translational scientists from industry, government, and academia
  • Drug and medical device product/clinical development team leader and members
  • Clinical pharmacology and development team leaders, pharmacists, and clinical scientists
  • Therapeutic area and technology platform managers
  • Regulatory scientists from industry, government, and academia
  • Portfolio, program, and project managers
  • Knowledge transfer, partnering, licensing, and legal experts
  • Heads of research and/or product development and business executives
  • Investors from venture funds and financial institutions
eligibility criteria

You must:

  • have a higher university degree, such as MD, PharmD, PhD, Master's or JD (Applicants without terminal degrees but with extensive product development will be considered)
  • have a primary interest in medical product discovery, development, regulation, or related activity
  • have at least one year of work experience in medical product development
  • be qualified via standards and nominations by submitting a one-page curriculum vitae to [email protected] prior to or immediately following registration

Enrollees are required to provide proof of full COVID-19 vaccination for in-person attendance. Per University of California policy, full COVID-19 vaccination status is defined as 14 days after receiving the single-dose Johnson & Johnson (Janssen) vaccine or 14 days after the second shot of the two-dose Moderna or Pfizer vaccines.

topics Content is comprehensive and interconnected. See topics and learning outcomes on the ACDRS 2022 Course page
learning methods lectures, team-involved case studies, discussions (including panels), online learning, intersession activities, and final examination
  • $13,500 before or on the early registration deadline
  • $15,000 after the early registration deadline
  • discounted fee for a limited number of participants from academia and government is available; contact [email protected] for details
administrative details Enrollment is limited; we encourage you to register well in advance.
If you cancel before the cancellation deadline specified on the 2022 Course details page, the fee less $500 for administrative expenses will be returned. 
contact [email protected]

ACDRS Workshop

  Workshop Description
day and time one day
who should attend open to all interested parties, including ACDRS alumni and faculty
topics one topic
learning methods lectures, panel discussions, and Q&A
fee registration fee amount provided when workshop announced
contact acdr[email protected]

ACDRS Webinar

  Webinar Description
day and time one-hour
who should attend open to all interested parties, including ACDRS alumni and faculty
topics one topic
learning methods lecture and Q&A
fee no cost
contact [email protected]
“I was very fortunate to participate in the ACDRS course early in my career in drug development The course provided real-world examples taught by thought-­leaders in the field from academia, regulatory agencies, and industry. Having classmates who also represented these co-operative facets of drug development enriched the experience by providing alternate viewpoints and opportunities for professional interactions.”
Kofi Mensah, Director, Early Development, Bristol Myers Squibb